These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10886042)

  • 1. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
    Houghton LA; Foster JM; Whorwell PJ
    Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: clinical pharmacology of alosetron.
    Gunput MD
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
    Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
    Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
    Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
    Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
    Simrén M; Simms L; D'Souza D; Abrahamsson H; Björnsson ES
    Aliment Pharmacol Ther; 2003 Jan; 17(2):279-87. PubMed ID: 12534414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
    Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alosetron.
    Balfour JA; Goa KL; Perry CM
    Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
    Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
    Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
    Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and clinical experience with alosetron.
    Camilleri M
    Expert Opin Investig Drugs; 2000 Jan; 9(1):147-59. PubMed ID: 11060667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
    Cremonini F; Delgado-Aros S; Camilleri M
    Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.